Results 51 to 60 of about 159,806 (339)

Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases

International Journal of Molecular Sciences, 2021
Over the last decades, antiplatelet agents, mainly aspirin and P2Y12 receptor antagonists, have significantly reduced morbidity and mortality associated with arterial thrombosis.
Georges Jourdi, M. Lordkipanidzé, A. Philippe, C. Bachelot-Loza, P. Gaussem   +4 more
semanticscholar   +1 more source

Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review

Health Technology Assessment, 2013
Background: Previous research suggests uncertainty whether or not there is any additional benefit in adding antiplatelet therapy (APT) to anticoagulation therapy (ACT) in patients with high-risk atrial fibrillation (AF) in terms of reduction in vascular ...
DA Lane, S Raichand, D Moore, M Connock, A Fry-Smith, DA Fitzmaurice, on behalf of the Steering Committee   +6 more
doaj   +1 more source

Laparoscopic total extraperitoneal inguinal hernia repair is safe and feasible in patients with continuation of antithrombotics

Journal of Minimal Access Surgery, 2019
Aims: We aimed to evaluate the safety and feasibility of laparoscopic total extraperitoneal (TEP) inguinal hernia repair in patients with the continuation of their antithrombotic agents. Settings and Design: This was prospective cohort study.
Chen-Hsun Ho, Chia-Chang Wu, Chao-Chuan Wu, Yao-Chou Tsai   +3 more
doaj   +1 more source

Effects of Periprocedural Tirofiban vs. Oral Antiplatelet Drug Therapy on Posterior Circulation Infarction in Patients With Acute Intracranial Atherosclerosis-Related Vertebrobasilar Artery Occlusion

Frontiers in Neurology, 2020
Background and purpose: Tirofiban and oral antiplatelet drugs can be used to inhibit reocclusion and restore microvascular reperfusion during endovascular treatment (EVT).
Xuan Sun, Huijun Zhang, Xu Tong, Feng Gao, Gaoting Ma, Zhongrong Miao   +5 more
doaj   +1 more source

Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]

, 2018
© The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast, AD Michelson, B Labarthe, B Shen, C Patrono, CT Ammollo, D Capodanno, D Gailani, DA Gorog, Diana A. Gorog, DM Coenen, E Álvarez, ER Bates, F Kabirian, F Müller, F Semeraro, G Stephens, H Brogren, HE Speich, HE Speich, HJ Weiss, HJ Weiss, HR Baumgartner, J Zilberman-Rudenko, JD McFadyen, JI Weitz, JM Cosemans, JP Collet, JP Collet, K Hosokawa, K Nagatsuka, KS Sakariassen, L Valerio, LF Brass, M Cattaneo, M Farag, M Humbert, M Larsson, M Li, M Ungerer, MA Bailey, MI Furman, MJ Price, ML Montfoort von, MS Sabatine, P Andre, P Seizer, PA Borne von dem, PP Wadowski, R Hellmuth, R Nergiz-Unal, RA Ajjan, S Goto, S Goto, SA Shaya, SB Larsen, SJ Marciniak, T Heitzer, T Renné, VT Turitto, VT Turitto, WA Schumacher, WS Nesbitt, X Wang, Y Yano, YC Lau, ZM Ruggeri   +66 more
core   +2 more sources

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2019
Importance Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with a drug-eluting stent may be an attractive option.
Hirotoshi Watanabe, T. Domei, T. Morimoto, M. Natsuaki, H. Shiomi, T. Toyota, M. Ohya, S. Suwa, K. Takagi, M. Nanasato, Yoshiki Hata, Masahiro Yagi, N. Suematsu, Takafumi Yokomatsu, I. Takamisawa, M. Doi, T. Noda, H. Okayama, Yoshitane Seino, T. Tada, H. Sakamoto, K. Hibi, M. Abe, K. Kawai, K. Nakao, K. Ando, K. Tanabe, Y. Ikari, K. Hanaoka, Y. Morino, K. Kozuma, K. Kadota, Y. Furukawa, Y. Nakagawa, Takeshi Kimura   +34 more
semanticscholar   +1 more source

Association of Antiplatelet Therapy, Including Cilostazol, With Improved Survival in Patients With Moyamoya Disease in a Nationwide Study

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2021
Background Although antiplatelet agents are frequently prescribed in moyamoya disease in routine clinical practice, there are no large‐scale epidemiologic trials or randomized trial evidence to support their use in patients with moyamoya disease. Methods
W. Seo, Jaeyoung Kim, Eun‐Hyeok Choi, Yesel Kim, Jong-Won Chung, J. Saver, O. Bang, Gyeong-Moon Kim   +7 more
semanticscholar   +1 more source

Embolic strokes of undetermined source: prevalence and patient features in the ESUS Global Registry [PDF]

, 2016
Background: Recent evidence supports that most non-lacunar cryptogenic strokes are embolic. Accordingly, these strokes have been designated as embolic strokes of undetermined source (ESUS).
Ameriso, Sebastian F, Arauz, Antonio, Berkowitz, Scott D, Bosch, Jackie, Brouns, Raf, Connolly, Stuart J, Coutinho, Jonathan, Cunha, Luis, Gagliardi, Rubens J, Giruparajah, Mohana, Hankey, Graeme J, Hart, Robert G, Kasner, Scott E, Kitagawa, Kazuo, Lavallee, Philippa, Mattina, Katie R, Muir, Keith, O\u2019Donnell, Martin J, Perera, Kanjana S, Pieroni, Alessio, Shamalov, Nikolay, Swaminathan, Balakumar, Vanassche, Thomas, Vastagh, Ildiko, Vermehren, Philipp, Wang, Yongjun, Yoon, Byung-Woo, Yperzeele, Laetitia   +27 more
core   +2 more sources

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. [PDF]

, 2020
Background Reducing major bleeding events is a challenge when managing anticoagulation in patients with atrial fibrillation. This study evaluated the impact of modifiable and nonmodifiable bleeding risk factors in patients with atrial fibrillation ...
Amarenco, P, Camm, AJ, Haas, S, Hess, S, Kirchhof, P, Lambelet, M, Turpie, AGG, van Eickels, M, XANTUS Investigators*   +8 more
core   +2 more sources

Antiplatelet agents for preventing pre-eclampsia and its complications.

Cochrane Database of Systematic Reviews, 2019
BACKGROUND Pre-eclampsia is associated with deficient intravascular production of prostacyclin, a vasodilator, and excessive production of thromboxane, a vasoconstrictor and stimulant of platelet aggregation. These observations led to the hypotheses that
L. Duley, S. Meher, K. Hunter, A. Seidler, L. Askie   +4 more
semanticscholar   +1 more source